Home Investment Sugar.fit Secures Additional $5 Million in Series A Funding Led by B...

Sugar.fit Secures Additional $5 Million in Series A Funding Led by B Capital.

0

Sugar.fit, a pioneering health-tech venture specializing in type 2 diabetes and prediabetes management, has raised an additional $5 million in its Series A funding round. The funding was spearheaded by B Capital, with noteworthy participation from MassMutual Ventures. It also received continued support from existing investors such as Tanglin Venture Partners, Endiya Partners, and Cure.fit (now Cult.fit).

This recent investment follows a successful Series A round in October of the previous year, during which Sugar.fit raised $11 million, led by MassMutual Ventures.

The infusion of fresh capital is earmarked for the augmentation of Sugar.fit’s technological infrastructure and product portfolio. Additionally, it will fuel an expansion of the brand’s presence in the market, enhance its brand visibility, and accelerate research and development endeavours in diabetes management, as articulated in a press release by the company.

Founded by Madan Somasundaram, Sugar.fit offers a comprehensive diabetes care program that seamlessly integrates cutting-edge technology with personalized human interventions. The program employs various devices, including continuous glucose monitors, fitness trackers, and health diagnostics. It allows diabetes specialists and nutritionists to monitor users’ glucose levels in real time and analyze the impact of lifestyle choices on their health.

Remarkably, Sugar.fit has experienced substantial growth in paid subscribers over the past 18 months, now catering to a user base exceeding 30,000 individuals. Moreover, the brand has solidified its presence across multiple channels, commencing operations in Bengaluru and establishing seven diabetes clinics with specialist care practitioners nationwide.

As Sugar.fit continues to innovate and expand its offerings in the realm of diabetes management, this latest round of funding underscores not only investor confidence but also the pressing need for transformative solutions in addressing the global epidemic of diabetes and related metabolic conditions.

NO COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Exit mobile version